Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma

Starting soon · Phase 1/Phase 2

Conditions studied: Uveal Melanoma

In brief

Neoadjuvant RBP-01 in patients with primary uveal melanoma.

Key facts

Study ID

NCT07747935

Run by

ReBio Pharma

People needed

30

Starts

2026-10-01

Expected to finish

2028-04-01

Last updated by the study team

2026-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female participants aged ≥18 years.
• Participants with choroidal and ciliary body [P13.1] tumours.
• Participants with primary localized UM requiring enucleation (Cohort 1) or plaque brachytherapy at high risk of vision loss (Cohort 2), as per investigator assessment.
• Participants with ECOG performance status 0-1.
• Tumour thickness > 4 mm.
• Females of child bearing potential must have a negative urine pregnancy test result at screening.

You may not qualify if…

• Participant has received previous treatment with a PKC inhibitor at any time.
• Participant has received a prior diagnosis of metastatic disease.
• Presence of a tumour originating from the iris.
• Presence of intractable untreatable raised intraocular pressure.
• Presence of ring melanoma.
• Presence of severe glaucoma or uveitis.
• Participant is under active treatment for any other macular condition.
• Female participants who are pregnant or lactating. 10. Participant is unable to follow protocol requirements.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.